This document provides information about Daiichi Sankyo's TaNeDS program, which stands for "Take a New challenge for Drug Discovery". The program aims to foster collaboration between academia and the pharmaceutical industry in drug discovery efforts. It discusses the history and expansion of the program from Japan to Europe. Key details include funding amounts provided to selected academic research projects, numbers of applications and selections each year, and the focus on oncology-related proposals.

1. Keiko Tamai
Daiichi Sankyo Co., Ltd.
September 6, 2016
Collaboration through TaNeDS programme

2. 2
Our Founders
- Isolation of Adrenaline
- Discovery of Taka-
Diastase
- The first Sankyo
president
- Discovery of Orizanin
(Vitamin B1)
- Establishment of the
basic theory of vitamins
- Sankyo scientific adviser
- Establishment of Daiichi
Pharmaceutical
- Launch of Salvarsan in
Japan
Umetaro SuzukiJokichi Takamine Katsuzaemon Keimatsu

3. 3
Our Global R&D Locations
Daiichi Sankyo Co., Ltd
(R&D)
Daiichi Sankyo RD Novare
(R&D)
Asubio Pharma (R&D)
Daiichi Sankyo Pharma
Development
Edison, NJ
(Development & Research
Inquiry)
Daiichi Sankyo Europe
Munich
(Development and
Pharmaceutical technology)
Daiichi Sankyo
China
(Development)
as of August 2016
Daiichi Sankyo Life
Science Research
Center in India
(DDR, infectious &
autoimmune )
Daiichi Sankyo Brazil
（Development）
Daiichi Sankyo Venezuela
(Development)
Plexxikon
Berkeley, CA
(oncology)
Research Development R&D
Tissue and Cell
Research Centre
Munich,
Martinsried (R)

4. 4
Headquarters
Affiliates
Production sites
Istanbul
Zurich
Vienna
Munich
London Amsterdam
Pfaffenhofen
Altkirch
Madrid
Lisbon
Rome
Dublin
Brussels
TCRM
Tissue and Cell Research
centre Munich
Our Products and Locations in Europe
Paris
ARB: Anti-hypertension
Anti-platelet agents
FXa inhibitor: Anticoagulant drug

5. 5
Major R&D pipeline
5
As of May 2016

6. 66
R&D Focus Therapeutic Areas
Research
Early
Stage
Late
Stage
LCM and
Markets
Discovery Priority Areas
• Oncology
• Pain
• Sensory Neuronal System
• Endo-organ Protection
• Rare Disease
Pain
(Mirogabalin)
Thrombotic
Disorders
(Efient,
Edoxaban)
Hypertension
(Olmetec)
Pain
(Loxoprofen)

7. 7
Open Innovation is the Key for Success
7

8. 8
Recent Research Alliances with ventures
and academiaBiologicsSmallMolecules
Venture Academia
National Cancer Center
Research Institute
産総研
The National Institute of
Advanced Industrial
Science and Technology

9. 9http://www.daiichisankyo.com/rd/open/index.html
Various channels for open innovation in DS

10. 10
TaNeDS Japan started from 2011
Recruitment of Research Projects From Academia in Japan
TaNeDS: Take a New challenge for Drug diScovery
Concept: Drug discovery project that is nurtured mutually by Academia & Pharma
Target Japanese academia to publicly solicit research on drug discovery seeds
that can be deployed to Daiichi Sankyo’s Research & Development
1. Wish List for Collaboration
Daiichi
Sankyo
Lab.
Academia
4. Collaboration
2. Application
3. Selection

11. Idea
&
Exploratory
Research
Enhancement
of exclusive
effects of
patents
Research stages
Validation of
technologies/
target
molecules
Working toward
practical use for
proprietary
technologies
Establishment
of concepts of
invention
Discovery of
technologies/
target
molecules
Extended Collaboration
Collaboration
in Japan
Extended Collaboration
Collaboration
in Europe
Criteria
Achieved
Concept of TaNeDS
(Take a New Challenge for Drug diScovery)
Japan: €40,000 – 80,000 per year, overhead included x 1 years
11
Europe: €100,000 – 150,000 per year, plus overhead x 2 years

12. 12
TaNeDS Global Programme started from 2013
The Programme has started
since July 2013 in
Germany, Switzerland and Austria

13. Candidate Profile
• Researchers affiliated with universities, research institutions
and/or small biotech in the EU plus, Norway and Switzerland.
• TaNeDS Europe is not open to undergraduates and graduate
students.
Selection Criteria
• Matching needs (Research Interests)
• Originality and uniqueness of research
• Possibility for drug generation
• Non-redundancy with Daiichi Sankyo’s internal research projects
Research Period
2 years
Funding Size
€100,000 – 150,000 per year, plus overhead
Eligibility, Funding size and other information
13
Brief view of TaNeDS Europe 2014

14. 14
TaNeDS: Japan vs Europe
Japan
(2011~2015)
Europe
(2013, 14)
Europe
(2015/16)
Funding
period
1 year 2 years 2 years
Funding
size
¥10 million ≒
€ 80K
including overhead
€100K – 150K/year
plus overhead
€100K – 150K/ye
or €50K – 80K/ye
plus overhead
Recognition
of DS
Very well
known Little known Little known
# of
Application
~ 250/year ~50/year ~200
# of
granted
~20/year
2/year
(though we had
budget for 5)
4

15. 15
Oncology related proposals dominated
(Summary results for TaNeDS 2013)
(The first campaign was performed only in Austria, Germany and
Switzerland.)
Fields of InterestNationality
Two oncology projects were selected.
University of Würzburg, Germany
Medical University of Innsbruck, Austria

16. 16
Summary of the 40 proposals for TaNeDS Global 2014
Subjects Countries
NAT: Nucleic Acid Therapeutics
2 Biologics (out of 6) and 2 SBDD (out of 5) proposals
moved to secondary evaluation. -> One each was selected.
Prescreening is not included
Biologics: Heidelberg Institute for Stem Cell Technology & Experimental Medicine
SBDD: University of Groningen, Netherland
SBDD: Structure-Based Drug Design

17. Idea
&
Exploratory
Research
Enhancement
of exclusive
effects of
patents
Research stages
Validation of
technologies/
target
molecules
Working toward
practical use for
proprietary
technologies
Establishment
of concepts of
invention
Discovery of
technologies/
target
molecules
Extended Collaboration
Type A
Collaboration
Extended Collaboration
Type B
Collaboration
Criteria
Achieved
Concept of TaNeDS
(Take a New Challenge for Drug diScovery)
Type A: €50,000 – 80,000 per year, plus overhead x 2 years
Type B: €100,000 – 150,000 per year, plus overhead x 2 years 17

18. 18
TaNeDS: Japan vs Europe
Japan
(2011~2015)
Europe
(2013, 14)
Europe
(2015/16)
Funding
period
1 year 2 years 2 years
Funding
size
¥10 million ≒
€ 80K
including overhead
€100K – 150K/year
plus overhead
€100K – 150K/year
or €50K – 80K/year
plus overhead
Recognition
of DS
Very well
known Little known Little known
# of
Application
~ 250/year ~50/year ~200
# of
granted
~20/year
2/year
(though we had
budget for 5)
4

19. 19
The summary of TaNeDS Europe 2015/16
Moving to second evaluation stage:
Four proposals from France
One proposal from
Germany, Switzerland, Ireland, Luxemburg, Sweden, Cyprus, Netherlands

20. 20
Summary: Application, Screening, Evaluation of TaNeDS 2015/16
4 proposals were selected at the end
Using NineSigma for
promotion
Received 191 proposals
Though the number is small,
all proposals moved to
interview stage

21. 21
Oncology
1. Small Molecules
2. Biologics
Pain/Sensory Neuron
1. Pain
2. Sensory neuronal systems
End-organ Protection
1. Heart
2. Stroke
3. Vascular
4. Kidney
5. Liver
6. Gastrointestinal
7. Fibrotic diseases
Other Diseases
1. Rare Diseases
2. Anaemia
3. Gut microbiome-related diseases
Cell Therapy
1. SSCs/PCs or PSC-DCs
2. Adoptive T cell therapy
Technology
1. Oncology
2. Engineering for Protein therapeutics
3. Nucleic acid therapeutics (NATs)
4. Gene therapy
5. Drug Metabolism and Pharmacokinetics
Area of interests for TaNeDS Europe 2017

22. 22
Schedule for TaNeDS Europe 2017
More detailed information will be coming soon at
http://www.daiichisankyo.com/rd/taneds/
Important Dates and Deadlines
• Start Date for Submission of Applications: January 10, 2017
• Submission Deadline: February 20, 2017, 23:59 CET
• Notification of Preliminary Decisions: Mid-March,
• Inquiry for Confidential Information under CDA: April
• On-site Visit Interview: Mid-May
• Notification of Final Decisions: Early-June
• Contract Negotiation: Early June to July
• Start of TaNeDS Research Programme: August/September

23. 23
Thank you!
Paljon kiitoksia!

24. Backup
24

25. Candidate Profile
• Researchers affiliated with universities, research institutions
and/or small biotech in the EU plus Iceland, Norway and
Switzerland.
• TaNeDS Europe is not open to undergraduates and graduate
students.
Selection Criteria
• Matching needs (Research Interests)
• Originality and uniqueness of research
• Possibility for drug generation
• Non-redundancy with Daiichi Sankyo’s internal research projects
Research Period
2 years
Funding Size
Type A: €50,000 – 80,000 per year, plus overhead
Type B: €100,000 – 150,000 per year, plus overhead
Eligibility, Funding size and other information
25
Brief view of TaNeDS Europe 2015/16

26. 26
* All selected projects are run by Junior PIs
Encouraging Junior PIs for submission
20
6
9
Career status of applicants
2014
Senior
Mid
Junior

27. Candidate Profile
• Researchers affiliated with universities, research institutions
and/or small biotech in the EU plus Iceland, Israel, Norway and
Switzerland.
• TaNeDS Europe is not open to undergraduates and graduate
students.
Selection Criteria
• Matching needs (Research Interests)
• Originality and uniqueness of research
• Possibility for drug generation
• Non-redundancy with Daiichi Sankyo’s internal research projects
Research Period
2 years
Funding Size
Type A: €50,000 – 80,000 per year, plus overhead
Type B: €100,000 – 150,000 per year, plus overhead
Eligibility, Funding size and other information
27
Brief view of TaNeDS Europe 2017

28. 28
Presentation Name | CONFIDENTIAL
Major Brands Global Sales FY2013
in blue frame: in-house products $1= JPY100
Brand
(generic name)
Mode of Action JPY in
Billion
US$ in
Million
Benicar/Olmetec
franchise
(olmesartan + CCB, HCTZ)
Angiotensin II receptor
blocker
300.2 3,002
Loxonin
(loxoprofen)
NSAID 59.3 593
Nexium
(esomeprazole)
Proton pump inhibitor 54.2 542
Welchol
(colesevelam)
Bile acid sequestrant 42.3 423
Cravit
(levofloxacin)
New quinolone 33.5 335
Memary
(memantin)
NMDA receptor antagonist 33.3 333
Venofer
(iron sucrose injection)
Iron deficiency anemia 24.9 249
Mevalotin
(pravastatin)
HMG-CoA reductase
inhibitor
22.4 224
Artist
(carvedilol)
Beta blocker 21.5 215
Effient/Efient
(prasugrel) *alliance revenue
ADP receptor antagonist 20.1 201

29. Our innovation history
29

30. Our innovation history
30